BAM
TEVA icon

Byrne Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Byrne Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.4K Sell
340
-100
-23% -$3.58K 0.01% 421
2026
Q2 		$14.9K Hold
440
– – 0.01% 389
2026
Q1 		$13.3K Sell
440
-120
-21% -$3.86K 0.01% 392
2025
Q4 		$17.5K Hold
560
– – 0.01% 366
2025
Q3 		$11.3K Sell
560
-100
-15% -$1.76K 0.01% 398
2025
Q2 		$11.1K Sell
660
-450
-41% -$7.26K 0.01% 391
2025
Q1 		$17.1K Hold
1,110
– – 0.01% 357
2024
Q4 		$24.5K Sell
1,110
-2,100
-65% -$38.2K 0.02% 265
2024
Q3 		$57.8K Hold
3,210
– – 0.04% 188
2024
Q2 		$52.2K Buy
+3,210
New +$49.4K 0.04% 192
2023
Q4 		– Sell
-200
Closed -$2K – 577
2023
Q3 		$2K Hold
200
– – ﹤0.01% 486
2023
Q2 		$2K Hold
200
– – ﹤0.01% 560
2023
Q1 		$2K Hold
200
– – ﹤0.01% 564
2022
Q4 		$1.82K Hold
200
– – ﹤0.01% 494
2022
Q3 		$2K Hold
200
– – ﹤0.01% 479
2022
Q2 		$2K Hold
200
– – ﹤0.01% 496
2022
Q1 		$2K Hold
200
– – ﹤0.01% 505
2021
Q4 		$2K Buy
+200
New +$1.8K ﹤0.01% 505

Other funds holding TEVA

WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return
IRC
Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return
VEM
Vann Equity Management Plano, Texas $168M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Byrne Asset Management's TEVA Position: Q3 2026 in Review

Byrne Asset Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 23% in Q3 2026, selling an estimated $3.58K and leaving 340 shares worth $13.4K. The position accounts for 0.01% of the portfolio, ranked #421.

Byrne Asset Management first reported a position in TEVA in Q4 2021 and has held it in 18 quarters since. The position peaked at $57.8K in Q3 2024. 10 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • Byrne Asset Management held 340 shares of Teva Pharmaceutical Industries Limited worth $13.4K as of Q3 2026.
  • Byrne Asset Management sold 100 Teva Pharmaceutical Industries Limited shares in Q3 2026, an estimated $3.58K.
  • Teva Pharmaceutical Industries Limited made up 0.01% of Byrne Asset Management's portfolio in Q3 2026, its #421 holding.
  • Byrne Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2021 and has held it in 18 quarters since.
  • Byrne Asset Management's Teva Pharmaceutical Industries Limited position peaked at $57.8K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on Byrne Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.